[Comment] JAVELIN: avelumab another spear to fight urothelial carcinoma

Single-agent immune checkpoint blockers targeting programmed death-1 receptor (PD-1) or its ligand PD-L1 have rapidly become standard treatment options for patients with advanced urothelial carcinoma after progression on platinum-based chemotherapy, and are evolving as a first-line option for platinum-ineligible patients.1 –4 Although the proportion of patients achieving a response in the second-line setting is only 15–25%, these responses are generally durable in conjunction with a favorable toxicity profile, which has led to substantial momentum to transition to an immunotherapy-based treatment approach from a c hemotherapy-based approach for all settings.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research